Objective: Although elevated uric acid is associated with obesity and considered a predictor of hypertension, the causal linkage between the three metabolic conditions is not very clear. We aim to examine whether elevated uric acid mediates the effects of obesity on hypertension development.
Methods: A total of 1984 participants (mean aged 53 years, 62.10% female) with repeated measurements of obesity, blood pressure, and uric acid 4 years apart in the Gusu cohort were included. We first applied cross-lagged panel analysis and bidirectional association analysis to delineate the temporal association between obesity and hyperuricemia. Then, a causal mediation model was constructed to further examine the causal role of hyperuricemia in the linkage between obesity and hypertension. Age, sex, education, cigarette smoking, alcohol consumption, fasting blood glucose, and lipids were adjusted.
Results: The cross-lagged panel analysis demonstrated that the relationship from baseline obesity to follow-up hyperuricemia was stronger than that from baseline hyperuricemia to follow-up obesity (β: 0.09 vs 0.06, <0.01 for BMI, β: 0.13 vs 0.07, <0.01 for WC). Bidirectional association analysis found that baseline obesity predicted the risk of incident hyperuricemia (OR = 1.09, <0.01 for BMI, OR = 1.05, <0.01 for WC), but the other directional association was not statistically significant (all >0.05). The causal mediation analysis found that hyperuricemia partially mediated the association of baseline BMI (mediate proportion: 3.09%, 95% CI: 0.97%~6.00% for SBP, 3.74%, 95% CI: 1.55%~7.00% for DBP) and baseline WC (mediate proportion: 5.56%, 95% CI: 2.01%~11.00% for SBP, 5.81%, 95% CI: 2.59%~10.00% for DBP) with follow-up blood pressures.
Conclusion: Obesity preceded hyperuricemia and the latter partially mediated the relationship between obesity and hypertension, independent of behavioral and other metabolic factors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012341 | PMC |
http://dx.doi.org/10.2147/CLEP.S363429 | DOI Listing |
Alzheimers Dement
December 2024
Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
Background: Dementia is a mental condition defined by a severe loss of intellectual ability that interferes with one's occupational or social activities. The rapid increase in the number of patients with dementia and Alzheimer's disease (AD) will result in tremendous consequences for our society and economy. Hypoxanthine is a purine compound that is implicated in the progression of AD.
View Article and Find Full Text PDFCurr Med Chem
January 2025
Department of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Background: Hyperuricemia (HUA) is a condition characterized by excessive uric acid production and/or inadequate uric acid excretion due to abnormal purine metabolism in the human body. Uric acid deposits resulting from HUA can lead to complications such as renal damage. Currently, drugs used to treat HUA lack specificity and often come with specific toxic side effects.
View Article and Find Full Text PDFFood Nutr Res
December 2024
Nutritional Epidemiology, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Background: Sweets, chocolate, and sweet bakery products are generally high in energy and added sugar, whereas the levels of essential nutrients and fibre are low. According to sales statistics, the consumption of sweets and chocolate is high in the Nordic and Baltic countries.
Objective: This scoping review describes the totality of evidence for the role of sweets and other sugary foods for health-related outcomes as a basis for setting and updating food-based dietary guidelines in the Nordic Nutrition Recommendations 2023 (NNR2023) project.
Cureus
December 2024
Department of Internal Medicine, Unidade Local de Saúde de São João, Porto, PRT.
Introduction: Hyperuricemia (HU) is associated with an increased risk of incident heart failure (HF) and adverse HF outcomes. Patients with diabetes mellitus (DM) have a greater prevalence of HU.
Aims: We evaluated the prognostic impact of HU in patients with HF according to the coexistence of DM.
Urolithiasis is a multifactorial condition where stone composition is critical in guiding treatment and prevention strategies. Advanced diagnostic techniques, such as infrared spectroscopy, provide precise stone analysis, enabling clinicians to tailor interventions based on specific stone types and associated metabolic abnormalities. Calcium oxalate monohydrate stones often require invasive approaches like percutaneous nephrolithotomy, while uric acid responds well to dissolution therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!